



## Supplementary Figure 2

**A**



**B**



**Figure S2.** Frequencies of CX3CR1<sup>+</sup> therapy-responsive CD8<sup>+</sup> T-cells remain unchanged after subsequent CIT in nonresponders. **A.** Percentage of CX3CR1<sup>+</sup>Granzyme B<sup>+</sup> cells in CD11a<sup>high</sup>CD8<sup>+</sup> T-cell population isolated from the peripheral blood obtained from 2 non-responders (black and green line) to CIT at multiple time points: prior to and after PD-1 therapy, the addition of chemotherapy and confirmed response to CIT (arrows indicate time points at treatment initiation and response assessment). The frequency of CX3CR1<sup>+</sup>Granzyme B<sup>+</sup> cells among CD11a<sup>high</sup>CD8<sup>+</sup> T-cells is unchanged after CIT in non-responders. **B.** Percentage of Bim<sup>+</sup> cells in CD11a<sup>high</sup>CD8<sup>+</sup> T cell population isolated from the peripheral blood obtained from the same patients with melanoma at same time points as in **A.**

CIT: Chemo-immunotherapy.